Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. A decade in biosecurity. Introduction.
暂无分享,去创建一个
[1] L. Price,et al. In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin , 2003, Antimicrobial Agents and Chemotherapy.
[2] D. Galas,et al. Global Science and U.S. Security , 2003, Science.
[3] Floyd E. Bloom,et al. Science as a Way of Life: Perplexities of a Physician-Scientist , 2003, Science.
[4] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[5] Anthony S. Fauci,et al. Biodefence on the research agenda , 2003, Nature.
[6] Thomas V Inglesby,et al. Biosecurity: responsible stewardship of bioscience in an age of catastrophic terrorism. , 2003, Biosecurity and bioterrorism : biodefense strategy, practice, and science.
[7] Janet M. Corrigan,et al. Priority areas for national action : transforming health care quality , 2003 .
[8] R. Eisenberg,et al. Bayh-Dole Reform and the Progress of Biomedicine , 2002, American Scientist.
[9] D. Geddes,et al. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis , 2002, Advanced Drug Delivery Reviews.
[10] A. Dahms,et al. The role of foreign worker scientists in the US biotechnology industry , 2002, Nature Biotechnology.
[11] Philip K. Russell,et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. , 2002, JAMA.
[12] Jerome Hauer,et al. Anthrax as a biological weapon, 2002: updated recommendations for management. , 2002, JAMA.
[13] David A. Edwards,et al. Delivery of biological agents by aerosols , 2002 .
[14] I. Brook,et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. , 2001, International journal of antimicrobial agents.
[15] Philip K. Russell,et al. Tularemia as a biological weapon: medical and public health management. , 2001, JAMA.
[16] J. DiMasi,et al. Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.
[17] Philip K. Russell,et al. Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.
[18] J. V. Moran,et al. Initial sequencing and analysis of the human genome. , 2001, Nature.
[19] V. Volchkov,et al. Recovery of Infectious Ebola Virus from Complementary DNA: RNA Editing of the GP Gene and Viral Cytotoxicity , 2001, Science.
[20] A. Ramsay,et al. Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox , 2001, Journal of Virology.
[21] L. Kohn,et al. To Err Is Human : Building a Safer Health System , 2007 .
[22] I. Brook,et al. In Vitro Development of Resistance to Ofloxacin and Doxycycline in Bacillus anthracis Sterne , 2000, Antimicrobial Agents and Chemotherapy.
[23] Philip K. Russell,et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 2000, JAMA.
[24] Juan Enriquez,et al. Transforming Life, Transforming Business: The Life Science Revolution , 2000 .
[25] Philip K. Russell,et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.
[26] T Friedmann,et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[27] D. Mccormick. Sequence the Human Genome , 1986, Bio/Technology.